MODIQUEST B.V.
ModiQuest specializes in the generation of monoclonal antibodies against difficult target antigens for R&D, diagnostic and therapeutic applications. Using its proprietary ModiFuse™ (hybridoma electrofusion), ModiSelect™ (B-cell selection) and ModiPhage™ (phage display) technologies, ModiQuest can generate very large panels of monoclonal antibodies from various backgrounds such as mouse, rat, rabbit, chicken, llama and human, as well as transgenic animals harboring the human immunoglobulin... (antibody) gene repertoire, against virtually any target. Besides antibody lead generation, ModiQuest also provides extensive antibody development and optimization procedures, such as affinity maturation, humanization, stable cell line generation and antibody production in transient and stable mammalian cell systems.
MODIQUEST B.V.
Social Links:
Industry:
Health Care Therapeutics
Founded:
2004-01-01
Status:
Active
Technology used in webpage:
SPF Google Font API Microsoft Exchange Online Amazon Office 365 Mail Google Maps Microsoft Azure DNS GoDaddy DNS GStatic Google Static Content AWS Global Accelerator
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-07-02 | Citryll | ModiQuest B.V. investment in Series B - Citryll | 18.5 M EUR |
| 2019-07-03 | Citryll | ModiQuest B.V. investment in Series A - Citryll | N/A |